Relation Therapeutics, a biotechnology firm based in London, UK, has raised $35 million in seed funding. The company uses computational and experimental techniques to medication discovery.
Leading the round, which raised the overall funding to $60 million, were DCVC and NVentures. Other participants included Jonathan Milner, the founder of Abcam, Khosla Ventures, and new investors ARK Invest and Deerfield Management Company.
The money will be used by the company to launch discovery efforts in new therapeutic areas with significant unmet need, as well as to progress its osteoporosis pipeline towards the clinic.
Relation Therapeutics, a biotechnology business with experimental and computational systems at its center that finds and develops transformative medications, is led by CEO David Roblin.
To better understand the molecular processes underlying human health and disease, the Lab-in-the-Loop technique combines functional tests, machine learning, and single cell multi-omics directly from patient tissue.
Utilizing insights from its data and technologies, the company is advancing programs, beginning with those connected to disorders of the bones.
Relation is creating osteoporosis treatments as a first step. Relation has developed a number of proprietary data resources as part of these initiatives, including as Osteomics, a clinical observational research aimed at producing a sizable, functioning single-cell bone atlas generated from patient tissue from humans.
